Miotics for Glaucoma: NBEO and OKAP Review
Learn how miotics lower IOP, when to use pilocarpine in angle closure and the adverse effects exams commonly test.
Pilocarpine lowers intraocular pressure in part by:
Miotics in 30 Seconds
Miotics are parasympathomimetic agents that constrict the pupil and contract the ciliary muscle. Pilocarpine is the classic miotic, a direct-acting muscarinic agonist acting primarily at M3 receptors. Today miotics are used primarily in selected glaucoma settings rather than as routine first-line therapy.
Mechanism and Effects
- Mechanism: muscarinic M3 receptor agonism contracts the ciliary muscle and iris sphincter pupillae. Exam relevance: pilocarpine is a direct-acting cholinergic agonist.
- Pupil: miosis (pupil constriction). Exam relevance: miosis helps relieve pupillary-block angle closure by pulling the peripheral iris away from the angle.
- Outflow: ciliary muscle contraction widens the trabecular meshwork and increases conventional aqueous outflow through Schlemm canal. Exam relevance: miotics lower IOP through the conventional, not uveoscleral, pathway.
- Accommodation: ciliary muscle contraction induces accommodation and may cause a myopic shift, particularly in younger patients. Exam relevance: near blur, brow ache and induced myopia are classic adverse effects.
- Lens: long-term use has been associated with lens changes including an increased risk of cataract formation. Exam relevance: this risk limits chronic miotic therapy.
- Night vision: persistent miosis limits retinal illumination and may reduce night vision. Exam relevance: reduced night vision is a classic patient complaint with chronic pilocarpine.
Clinical Uses
- Open-angle glaucoma: historically first-line, now reserved for selected patients because prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors, alpha agonists and laser trabeculoplasty are generally preferred. Exam relevance: pilocarpine is no longer routine initial therapy for open-angle glaucoma.
- Acute angle closure: add pilocarpine after initial IOP reduction, since very high IOP impairs iris sphincter response. Exam relevance: timing of pilocarpine relative to IOP reduction is a classic board question.
- Accommodative esotropia: echothiophate historically reduced accommodative convergence in high AC/A ratio esotropia. Exam relevance: spectacle correction has largely replaced miotic therapy.
4 Facts Exams Always Ask
- Pilocarpine is a direct-acting muscarinic M3 agonist that causes miosis and opens the trabecular meshwork via ciliary muscle contraction and increased outflow through Schlemm canal.
- In acute angle closure, pilocarpine should be given after initial IOP lowering because markedly elevated IOP paralyzes the iris sphincter through ischemia.
- Long-term miotic use can cause a myopic shift from ciliary spasm, reduced night vision, and an increased risk of cataract formation.
- Miotics are contraindicated in malignant glaucoma because ciliary muscle contraction worsens aqueous misdirection. Plateau iris requires treatment of the anatomic configuration with laser peripheral iridoplasty rather than reliance on miotics alone.
The Classic Trap
The first trap is giving pilocarpine as the first drug in acute angle closure before IOP is reduced. At very high IOP, iris sphincter ischemia limits miosis. The second trap is using miotics in malignant glaucoma, where ciliary muscle contraction worsens aqueous misdirection. Plateau iris syndrome requires laser peripheral iridoplasty to treat the underlying anatomy, not miotics alone.
Clinical Pearl
Pilocarpine remains relevant in two situations: acute angle closure after IOP reduction and as a second-line agent in selected open-angle glaucoma patients. Its myopic shift, accommodative symptoms, night vision reduction and cataract risk explain why prostaglandin analogs and beta-blockers have largely replaced miotics as first-line glaucoma agents. In patients with pre-existing peripheral retinal lesions, pilocarpine carries an increased risk of retinal detachment through ciliary body contraction and vitreoretinal traction.
Checkpoint 1
Pilocarpine lowers intraocular pressure predominantly by which mechanism in open-angle glaucoma?
Checkpoint 2
What pupillary effect does pilocarpine produce?
A 61-year-old patient presents with severe unilateral ocular pain, nausea, corneal edema, a mid-dilated pupil and markedly elevated IOP. The clinician administers topical aqueous suppressants and systemic IOP-lowering therapy. Which medication should be added next to pull the peripheral iris away from the trabecular meshwork, and when?
A patient with acute angle closure has received topical aqueous suppressants and systemic IOP-lowering therapy. When is the appropriate time to add pilocarpine?
Sources & Publisher Info
Last clinically reviewed: August 9, 2026
References
- American Academy of Ophthalmology. Basic and Clinical Science Course, Section 10: Glaucoma.
- American Academy of Ophthalmology. Basic and Clinical Science Course, Section 3: Clinical Optics.
- American Academy of Ophthalmology. EyeWiki: Pilocarpine and Miotics.
More Pharmacology topics
Ready for the real thing?
Practice thousands of eye-care questions free on OcuQuiz. Earn points, build streaks and battle colleagues.
Practice Pharmacology →